GSK’s Mosquirix Effective?

The world’s first malaria vaccine has cleared one of the final hurdles prior to being approved for use in Africa.

The European Medicines Agency gave a positive scientific opinion after assessing its safety and effectiveness.

“Kids in Africa will benefit from it,” said Joe Cohen, co-inventor of the vaccine ‘mosquirix’.

“The target population is kids under the age of 5.”

The vaccine will not stop malaria, but will add onto the benefits of other prevention measures, said Dr Fatoumata Nafo-Traore, executive director of the “Roll Back Malaria Partnership”.

“It is an important achievement and we appreciate the positive feedback,” she added.

Malaria kills around 584,000 people a year worldwide, most of them children under five in sub-Saharan Africa.

Note: The vaccine will NOT STOP malaria, so there goes any claim of effectiveness. Only 1 in 3 maybe protected! Also requires 4 injections (introduction of toxins and dna altering vectors) for children between the ages of 6 weeks to 17 months.
The same WHO that refuses to allow open testing of contaminated Tetanus vaccines in Kenya will now distribute this malaria “vaccine”.

1 thought on “GSK’s Mosquirix Effective?

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s